High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors

Assay and Drug Development Technologies

Volumn 8, Issue 1, 2010, Pages 37-46

  Saunders, Matthew J ^a,b,c   Graves, Steven W ^b,c   Sklar, Larry A ^a   Oprea, Tudor I ^a   Edwards, Bruce S ^a  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^b University of New Mexico   (United States)

^c LOS ALAMOS NATIONAL LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A; EBSELEN; ELEMENT; HYBRID PROTEIN; MICROSPHERE; PROTEINASE INHIBITOR; SYNAPTOSOMAL ASSOCIATED PROTEIN 25;

ARTICLE; BIOASSAY; CONTROLLED STUDY; DELETION MUTANT; DRUG BIOAVAILABILITY; FLOW CYTOMETRY; HIGH THROUGHPUT SCREENING; IN VITRO STUDY; LIGHT CHAIN; NONHUMAN; PATENT; VALIDITY;

ANTIGENS, BACTERIAL; AZOLES; BACTERIAL TOXINS; BOTULINUM TOXIN TYPE A; DRUG EVALUATION, PRECLINICAL; FLOW CYTOMETRY; FLUORESCENCE RESONANCE ENERGY TRANSFER; HIGH-THROUGHPUT SCREENING ASSAYS; METALLOPROTEASES; MICROSPHERES; ORGANOSELENIUM COMPOUNDS; PROTEASE INHIBITORS;

EID: 77649152201     PISSN: 1540658X     EISSN: None     Source Type: Journal    
DOI: 10.1089/adt.2009.0219     Document Type: Article

References (33)

1. Hooper NM: Proteases: a primer. Essays in Biochemistry: Proteases in Biology and Medicine. Volume 38. London, UK: Portland Press; 2002: 1-8.
2. Southan C: A genomic perspective on human proteases as drug targets. Drug Discov Today 2001;6(13):681-688.
3. Cruz-Munoz W, Khokha R: The role of tissue inhibitors of metalloproteinases in tumorigenesis and metastasis. Crit Rev Clin Lab Sci 2008;45(3):291-338.
4. Patick AK, Potts KE: Protease inhibitors as antiviral agents. Clin Microbiol Rev 1998;11(4):614-627.
5. Bigalke H, Rummel A: Medical aspects of toxin weapons. Toxicology 2005;214(3):210-220.
6. Johnson EA. Clostridial toxins as therapeutic agents: Benefits of nature's most toxic proteins. Annu Rev Microbiol 1999;53:551-575.
7. Breidenbach MA, Brunger AT: New insights into clostridial neurotoxin-SNARE interactions. Trends Mol Med 2005;11(8):377-381.
8. Arnon SS, Schechter R, Inglesby TV, Henderson DA, Bartlett JG, Ascher MS, et al.: Botulinum toxin as a biological weapon: Medical and public health management. JAMA 2001;285(16):2081.
9. Rossetto O, Schiavo G, Montecucco C, Poulain B, Deloye F, Lozzi L, et al.: Snare motif and neurotoxins. Nature 1994;372(6505):415-416.
10. Washbourne P, Pellizzari R, Baldini G, Wilson MC, Montecucco C: Botulinum neurotoxin types A and E require the SNARE motif in SNAP-25 for proteolysis. FEBS Lett 1997;418(1-2):1-5.
11. Vaidyanathan VV, Yoshino K, Jahnz M, Dörries C, Bade S, Nauenburg S, et al.: Proteolysis of SNAP-25 isoforms by botulinum neurotoxin types A, C, and E: Domains and amino acid residues controlling the formation of enzyme-substrate complexes and cleavage. J Neurochem 1999;72(1):327-337.
12. Breidenbach MA, Brunger AT: Substrate recognition strategy for botulinum neurotoxin serotype A. Nature 2004;432(7019):925-929.
13. Eubanks LM, Hixon MS, Jin W, Hong S, Clancy CM, Tepp WH, et al.: An in vitro and in vivo disconnect uncovered through high-throughput identification of botulinum neurotoxin A antagonists. Proc Natl Acad Sci USA 2007;104(8):2602- 2607.
14. Boldt GE, Kennedy JP, Hixon MS, McAllister LA, Barbieri JT, Tzipori S, et al.: Synthesis, characterization and development of a high-throughput methodology for the discovery of botulinum neurotoxin A inhibitors. J Comb Chem 2006;8(4):513-521.
15. Hines HB, Kim AD, Stafford RG, Badie SS, Brueggeman EE, Newman DJ, et al.: Use of a recombinant fluorescent substrate with cleavage sites for all botulinum neurotoxins in high-throughput screening of natural product extracts for inhibitors of serotypes A, B, and E. Appl Environ Microbiol 2008;74(3):653-659.
16. Nagase H, Woessner JF, Jr.: Matrix metalloproteinases. J Biol Chem 1999;274(31):21491-21494.
17. Hase CC, Finkelstein RA: Bacterial extracellular zinc-containing metalloproteases. Microbiol Rev 1993;57(4):823-837.
18. Saunders MJ, Kim H, Woods TA, Nolan JP, Sklar LA, Edwards BS, et al.: Microsphere-based protease assays and screening application for lethal factor and factor Xa. Cytometry A 2006;69(5):342-352.
19. Sklar LA, Edwards BS, Graves SW, Nolan JP, Prossnitz ER.: Flow cytometric analysis of ligand-receptor interactions and molecular assemblies. Annu Rev Biophys Biomol Struct 2002;31:97-119.
20. Edwards BS, Kuckuck FW, Prossnitz ER, Ransom JT, Sklar LA: HTPS flow cytometry: A novel platform for automated high throughput drug discovery and characterization. J Biomol Screen 2001;6(2):83-90.
21. Kuckuck FW, Edwards BS, Sklar LA: High throughput flow cytometry. Cytometry 2001;44(1):83-90.
22. Nikawa T, Schuch G, Wagner G, Sies H: Interaction of ebselen with glutathione-S-transferase and papain in-vitro. Biochem Pharmacol 1994;47(6):1007-1012.
23. Eubanks LM, Hixon MS, Jin W, Hong S, Clancy CM, Tepp WH, et al.: An in vitro and in vivo disconnect uncovered through high-throughput identification of botulinum neurotoxin A antagonists. Proc Natl Acad Sci USA 2007;104(15):6490
24. Bubolz AH, Wu QP, Larsen BT, Gutterman DD, Liu YP: Ebselen reduces nitration and restores voltage-gated potassium channel function in small coronary arteries of diabetic rats. Am J Physiol Heart Circ Physiol 2007;293(4):H2231-H2237.
25. Schewe T: Molecular actions of ebselen-an antiinflammatory antioxidant. Gen Pharmacol 1995;26(6):1153-1169.
26. Takasago T, Peters EE, Graham DI, Masayasu H, Macrae IM: Neuroprotective efficacy of ebselen, an anti-oxidant with antiinflammatory actions, in a rodent model of permanent middle cerebral artery occlusion. Br J Pharmacol 1997;122(6):1251-1256.
27. Tunc T, Uysal B, Atabek C, Kesik V, Caliskan B, Oztas E, et al.: Erdosteine and ebselen as useful agents in intestinal ischemia/reperfusion injury. J Surg Res 2009;155(2):210-216.
28. Billack B, Santoro M, Lau-Cam C: Growth inhibitory action of ebselen on fluconazole-resistant Candida albicans: Role of the plasma membrane H+-ATPase. Microb Drug Resist 2009;15(2):77-83.
29. Pietka-Ottlik M, Wojtowicz-Mlociiowska H, Kolodziejczyk K, Piasecki E, Mlochowski J: New organoselenium compounds active against pathogenic bacteria, fungi and viruses. Chem Pharm Bull 2008;56(10):1423-1427.
30. Sakurai T, Kanayama M, Shibata T, Itoh K, Kobayashi A, Yamamoto M, et al.: Ebselen, a seleno-organic antioxidant, as an electrophile. Chem Res Toxicol 2006;19(11):1557.
31. Willis B, Eubanks LM, Dickerson TJ, Janda KD: The strange case of the botulinum neurotoxin: Using chemistry and biology to modulate the most deadly poison. Angew Chem Int Ed Engl 2008;47(44):8360-8379.
32. Eubanks LM, Dickerson TJ: Investigating novel therapeutic targets and molecular mechanisms to treat botulinum neurotoxin A intoxication. Future Microbiol 2007;2(6):677-687.
33. Handa Y, Kaneko M, Takeuchi H, Tsuchida A, Kobayashi H, Kubota T: Effect of an antioxidant, ebselen, on development of chronic cerebral vasospasm after subarachnoid hemorrhage in primates. Surg Neurol 2000;53(4):323-329.